Unmet needs in retinal disease, from clinical endpoints to new therapies, focused on GLAUCOMA and retinal ganglion cell NEUROPROTECTION.
Investor R&D Day, July 16, 2025: THREE LATE-PHASE ASSETS, with Dr. Charles Wykoff and Dr. Sumit Sharma. Strong 12-week APEX data for KSI-101.
POSITIVE GLOW2 Phase 3 results: Zenkuda™ dosed every 6 months, 62.5% ≥2-step DRSS improvement vs 3.3% sham. BLA-READY profile.
Final Week 24 APEX results for KSI-101 in MESI: over half gained ≥15 LETTERS, >90% fluid resolution. Now in PHASE 3 PEAK and PINNACLE.
